APA (7th ed.) Citation

Leng, X., Leszczynski, P., Jeka, S., Liu, S., Liu, H., Miakisz, M., . . . Zeng, X. (2022). POS0287 A PHASE III, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED CLINICAL TRIAL TO COMPARE BAT1806/BIIB800, A PROPOSED TOCILIZUMAB BIOSIMILAR, WITH TOCILIZUMAB REFERENCE PRODUCT IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE THERAPY. Annals of the rheumatic diseases, 81, 388. https://doi.org/10.1136/annrheumdis-2022-eular.515

Chicago Style (17th ed.) Citation

Leng, X., et al. "POS0287 A PHASE III, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED CLINICAL TRIAL TO COMPARE BAT1806/BIIB800, A PROPOSED TOCILIZUMAB BIOSIMILAR, WITH TOCILIZUMAB REFERENCE PRODUCT IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE THERAPY." Annals of the Rheumatic Diseases 81 (2022): 388. https://doi.org/10.1136/annrheumdis-2022-eular.515.

MLA (9th ed.) Citation

Leng, X., et al. "POS0287 A PHASE III, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED CLINICAL TRIAL TO COMPARE BAT1806/BIIB800, A PROPOSED TOCILIZUMAB BIOSIMILAR, WITH TOCILIZUMAB REFERENCE PRODUCT IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE THERAPY." Annals of the Rheumatic Diseases, vol. 81, 2022, p. 388, https://doi.org/10.1136/annrheumdis-2022-eular.515.